Orlando M Gutiérrez1, Marguerite R Irvin2, Neil A Zakai3, Rakhi P Naik4, Ninad S Chaudhary2, Michelle M Estrella5, Sophie Limou6, Suzanne E Judd7, Mary Cushman8, Jeffrey B Kopp9, Cheryl A Winkler10. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL. 2. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL. 3. Departments of Medicine and Pathology, Robert Larner College of Medicine, University of Vermont, Burlington, VT. 4. Department of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD. 5. Kidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA; San Francisco VA Medical Center, San Francisco, CA. 6. University of Nantes, Nantes, France. 7. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL. 8. Departments of Medicine and Pathology, Robert Larner College of Medicine, University of Vermont, Burlington, VT; Department of Laboratory Medicine, Robert Larner College of Medicine, University of Vermont, Burlington, VT. 9. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 10. Basic Research Program, Frederick National Laboratory for Cancer Research, Frederick, MD. Electronic address: winklerc@mail.nih.gov.
Abstract
RATIONALE & OBJECTIVE: APOL1 nephropathy risk alleles are associated with the development of chronic kidney disease (CKD) in African Americans. Although CKD is an established risk factor for mortality, associations of APOL1 risk alleles with mortality are uncertain. STUDY DESIGN: Prospective cohort. SETTINGS & PARTICIPANTS: 10,380 African American and 17,485 white American participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. EXPOSURES: APOL1 nephropathy risk alleles. OUTCOMES: All-cause and cause-specific mortality. ANALYTICAL APPROACH: Cox proportional hazards models were used to examine the association of APOL1 high-risk genotypes (2 risk alleles) versus APOL1 low-risk genotypes (0/1 risk allele) with all-cause and cause-specific mortality in African Americans and examine the risk for all-cause mortality in African Americans with high-risk genotypes versus African Americans with low-risk genotypes and white Americans. RESULTS: APOL1 high-risk participants were younger and had a higher prevalence of albuminuria than low-risk participants. There was no statistically significant association of APOL1 high- versus low-risk genotypes with all-cause mortality in models adjusted for sociodemographic variables, comorbid conditions, and kidney function (HR, 0.88; 95% CI, 0.77-1.01). After further adjustment for genetic ancestry in a subset with available data, a statistically significant association emerged (HR, 0.81; 95% CI, 0.69-0.96). Associations differed by CKD status (Pinteraction=0.04), with African Americans with high-risk genotypes having lower risk for mortality than those with low-risk genotypes in fully adjusted models (HR, 0.78; 95% CI, 0.62-0.99) among those with CKD, but not those without CKD (HR, 0.84; 95% CI, 0.66-1.05). Compared with white Americans, African Americans with high-risk genotypes had a similar rate of mortality, whereas African Americans with low-risk genotypes had a higher rate of mortality (HR, 1.07; 95% CI, 1.00-1.14) in fully adjusted models. LIMITATIONS: Lack of follow-up measures of kidney function. CONCLUSIONS: African Americans with high-risk APOL1 genotypes had lower mortality than those with low-risk genotypes in multivariable-adjusted models including genetic ancestry. Published by Elsevier Inc.
RATIONALE & OBJECTIVE: APOL1 nephropathy risk alleles are associated with the development of chronic kidney disease (CKD) in African Americans. Although CKD is an established risk factor for mortality, associations of APOL1 risk alleles with mortality are uncertain. STUDY DESIGN: Prospective cohort. SETTINGS & PARTICIPANTS: 10,380 African American and 17,485 white American participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. EXPOSURES: APOL1 nephropathy risk alleles. OUTCOMES: All-cause and cause-specific mortality. ANALYTICAL APPROACH: Cox proportional hazards models were used to examine the association of APOL1 high-risk genotypes (2 risk alleles) versus APOL1 low-risk genotypes (0/1 risk allele) with all-cause and cause-specific mortality in African Americans and examine the risk for all-cause mortality in African Americans with high-risk genotypes versus African Americans with low-risk genotypes and white Americans. RESULTS: APOL1 high-risk participants were younger and had a higher prevalence of albuminuria than low-risk participants. There was no statistically significant association of APOL1 high- versus low-risk genotypes with all-cause mortality in models adjusted for sociodemographic variables, comorbid conditions, and kidney function (HR, 0.88; 95% CI, 0.77-1.01). After further adjustment for genetic ancestry in a subset with available data, a statistically significant association emerged (HR, 0.81; 95% CI, 0.69-0.96). Associations differed by CKD status (Pinteraction=0.04), with African Americans with high-risk genotypes having lower risk for mortality than those with low-risk genotypes in fully adjusted models (HR, 0.78; 95% CI, 0.62-0.99) among those with CKD, but not those without CKD (HR, 0.84; 95% CI, 0.66-1.05). Compared with white Americans, African Americans with high-risk genotypes had a similar rate of mortality, whereas African Americans with low-risk genotypes had a higher rate of mortality (HR, 1.07; 95% CI, 1.00-1.14) in fully adjusted models. LIMITATIONS: Lack of follow-up measures of kidney function. CONCLUSIONS: African Americans with high-risk APOL1 genotypes had lower mortality than those with low-risk genotypes in multivariable-adjusted models including genetic ancestry. Published by Elsevier Inc.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman Journal: Nephrol Dial Transplant Date: 2015-07-06 Impact factor: 5.992
Authors: Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: Kenneth J Mukamal; Joseph Tremaglio; David J Friedman; Joachim H Ix; Lewis H Kuller; Russell P Tracy; Martin R Pollak Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-03 Impact factor: 8.311
Authors: Jasmin Divers; Nicholette D Palmer; Carl D Langefeld; W Mark Brown; Lingyi Lu; Pamela J Hicks; S Carrie Smith; Jianzhao Xu; James G Terry; Thomas C Register; Lynne E Wagenknecht; John S Parks; Lijun Ma; Gary C Chan; Sarah G Buxbaum; Adolfo Correa; Solomon Musani; James G Wilson; Herman A Taylor; Donald W Bowden; John Jeffrey Carr; Barry I Freedman Journal: BMC Genet Date: 2017-12-08 Impact factor: 2.797
Authors: Kaoru Ito; Alexander G Bick; Jason Flannick; David J Friedman; Giulio Genovese; Michael G Parfenov; Steven R Depalma; Namrata Gupta; Stacey B Gabriel; Herman A Taylor; Ervin R Fox; Christopher Newton-Cheh; Sekar Kathiresan; Joel N Hirschhorn; David M Altshuler; Martin R Pollak; James G Wilson; J G Seidman; Christine Seidman Journal: Circ Res Date: 2013-12-30 Impact factor: 17.367
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112
Authors: Adriana M Hung; Shailja C Shah; Alexander G Bick; Zhihong Yu; Hua-Chang Chen; Christine M Hunt; Frank Wendt; Otis Wilson; Robert A Greevy; Cecilia P Chung; Ayako Suzuki; Yuk-Lam Ho; Elvis Akwo; Renato Polimanti; Jin Zhou; Peter Reaven; Philip S Tsao; J Michael Gaziano; Jennifer E Huffman; Jacob Joseph; Shiuh-Wen Luoh; Sudha Iyengar; Kyong-Mi Chang; Juan P Casas; Michael E Matheny; Christopher J O'Donnell; Kelly Cho; Ran Tao; Katalin Susztak; Cassianne Robinson-Cohen; Sony Tuteja; Edward D Siew Journal: JAMA Intern Med Date: 2022-04-01 Impact factor: 21.873
Authors: Ninad S Chaudhary; Nicole D Armstrong; Bertha A Hidalgo; Orlando M Gutiérrez; Jacklyn N Hellwege; Nita A Limdi; Richard J Reynolds; Suzanne E Judd; Girish N Nadkarni; Leslie Lange; Cheryl A Winkler; Jeffrey B Kopp; Donna K Arnett; Hemant K Tiwari; Marguerite R Irvin Journal: Front Med (Lausanne) Date: 2022-09-28